US prevalence
98M US adults
Source: CDC 2024
ConditionICD-10: R73.03
Prediabetes
Prediabetes is elevated blood sugar that has not yet reached the diabetes threshold (A1c 5.7–6.4% or fasting glucose 100–125 mg/dL). ~96 million Americans have prediabetes and 80% don't know it. The good news: with diet, exercise, and sometimes medication, progression to type 2 diabetes can be slowed or reversed entirely.
Quick answer
UpdatedPrediabetes is elevated blood glucose below the diagnostic threshold for type 2 diabetes (A1C 5.7-6.4% or fasting glucose 100-125 mg/dL). Approximately 98 million US adults have prediabetes, with ~30% progressing to T2D within 5 years without intervention. GLP-1s are not yet FDA-approved specifically for prediabetes but show evidence of reducing progression — Wegovy SELECT-trial subset analysis showed lower diabetes-incidence in obese prediabetic patients.
- US prevalence: 98 million adults (~38%)
- CDC National Diabetes Statistics 2024
- Progression risk: ~30% to T2D within 5 years
- Without lifestyle intervention
- Diagnostic criteria: A1C 5.7-6.4% OR FPG 100-125 mg/dL
- ADA Standards of Care 2024
- GLP-1 evidence: Reduced T2D incidence in obese prediabetics
- SELECT trial subgroup; not FDA-approved indication
- First-line therapy: Diabetes Prevention Program (DPP) lifestyle intervention
- 58% T2D reduction over 3 years
Last clinical review
By GLP1Zoom editorial board
GLP-1 role
Not FDA-approved for prediabetes alone but used off-label in patients with concurrent obesity. Lifestyle intervention (Diabetes Prevention Program) remains first-line.
Key takeaways
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • First-line is still lifestyle change + metformin.
- • Coverage for prediabetes alone is rarely granted by payers.
Key facts
- •96 million US adults have prediabetes (CDC)
- •15–30% progress to type 2 diabetes within 5 years without intervention
- •Lifestyle intervention reduces progression risk by 58% (DPP study)
- •GLP-1 medications reduce progression risk by 60–70% in clinical trials
- •Insurance coverage for prediabetes is limited — most plans require T2D diagnosis
Why GLP-1 medications
For high-risk prediabetes patients (BMI ≥ 25, family history, gestational diabetes history), GLP-1 medications combined with diet + exercise can normalize blood sugar. Wegovy 2.4 mg has FDA approval for weight management — secondary effect lowers A1c and improves insulin sensitivity. Off-label use in pure prediabetes is increasing.
GLP-1 drugs prescribed for Prediabetes
Each row links to its full review with current pricing, FDA status, and the best telehealth providers offering it. Discuss with your prescriber — these are treatment options, not personal recommendations.
- Wegovy$1349–$1500/mo
semaglutide
78/100 matchOff-label for pure prediabetes; on-label if BMI ≥30 or ≥27 with comorbidity
Compare providers - Ozempic$968–$1100/mo
semaglutide
70/100 matchOff-label for prediabetes — strong evidence for progression-risk reduction
Compare providers - Zepbound$349–$1086/mo
tirzepatide
78/100 matchOff-label for prediabetes; on-label if BMI threshold met
Compare providers - Mounjaro$1023–$1330/mo
tirzepatide
72/100 matchOff-label for prediabetes — strongest evidence for progression-risk reduction
Compare providers
| Drug | Avg monthly cost | Indication match | Notes | Best providers |
|---|---|---|---|---|
| Wegovy semaglutide | $1349–$1500/mo | 78/100 | Off-label for pure prediabetes; on-label if BMI ≥30 or ≥27 with comorbidity | Compare |
| Ozempic semaglutide | $968–$1100/mo | 70/100 | Off-label for prediabetes — strong evidence for progression-risk reduction | Compare |
| Zepbound tirzepatide | $349–$1086/mo | 78/100 | Off-label for prediabetes; on-label if BMI threshold met | Compare |
| Mounjaro tirzepatide | $1023–$1330/mo | 72/100 | Off-label for prediabetes — strongest evidence for progression-risk reduction | Compare |
Educational only. Discuss with your prescriber — these are treatment options, not personal recommendations. Indication-match scores reflect FDA approval status and published clinical evidence, not individual patient suitability.
Common symptoms
- Usually asymptomatic — detected only on lab work
- Skin tags or dark patches (acanthosis nigricans) in some patients
- Some patients report fatigue or mild thirst (rare in prediabetes)
How prediabetes is diagnosed
A1c 5.7–6.4% OR fasting plasma glucose 100–125 mg/dL OR 2-hr OGTT 140–199 mg/dL. CDC recommends screening every 3 years starting at age 35, or earlier if overweight + risk factors. Many primary care visits now include automatic A1c screening.
Treatment options
Diabetes Prevention Program (DPP)
CDC-recognized lifestyle program — 22 weekly group sessions + 1-year maintenance. Goal: 5–7% body weight loss + 150 min/wk exercise. Reduces T2D risk by 58%. Now covered by Medicare and most insurance.
Metformin
Off-label for prediabetes prevention. Reduces T2D risk by ~31% (less than DPP but easier to maintain). Best for BMI ≥ 35, age < 60, gestational diabetes history.
GLP-1 medications
Off-label for pure prediabetes. Reduces progression by 60–70%. Cost barrier — most insurance excludes for prediabetes-only diagnosis.
Lifestyle changes alone
For low-to-moderate risk: targeted diet + exercise without formal DPP. Less effective but appropriate for younger, slimmer patients.
Compare telehealth providers for Prediabetes
SponsoredRanked by our editorial score. Visit a partner to check current pricing and eligibility — we never sell medications.
Advertising disclosure: we may earn a commission if you sign up through these links, at no extra cost to you — it never affects our rankings. How we make money
Lifestyle & self-care
- Lose 5–7% body weight if overweight (most powerful intervention)
- 150+ min/week moderate exercise (walking briskly counts)
- Reduce sugary drinks, refined carbs, ultra-processed foods
- Increase fiber (25g/day women, 38g/day men)
- Limit alcohol — empty calories that destabilize blood sugar
- Re-test A1c every 6–12 months to track progress
When to see a doctor
Make an appointment if you have:
- →Age ≥ 35 (CDC screening recommended)
- →BMI ≥ 25 + sedentary lifestyle
- →Family history of T2D
- →Gestational diabetes during pregnancy
- →Polycystic ovary syndrome (PCOS)
- →High blood pressure or cholesterol
Medications for Prediabetes
Wegovy
semaglutide
GLP1Zoom score: 8.9/10
From $1349/mo
Ozempic
semaglutide
GLP1Zoom score: 5.8/10
From $968/mo
Zepbound
tirzepatide
GLP1Zoom score: 9.3/10
From $349/mo
Mounjaro
tirzepatide
GLP1Zoom score: 6.6/10
From $1023/mo
Not sure which medication is right for you?
Take our 60-second quiz and get a personalized match.
Take the quizPrediabetes& GLP-1 — frequently asked questions
Can GLP-1 medications treat Prediabetes?
For high-risk prediabetes patients (BMI ≥ 25, family history, gestational diabetes history), GLP-1 medications combined with diet + exercise can normalize blood sugar. Wegovy 2.4 mg has FDA approval for weight management — secondary effect lowers A1c and improves insulin sensitivity. Off-label use in pure prediabete…
Which GLP-1 medications are used for Prediabetes?
GLP-1 options associated with Prediabetes include Ozempic, Wegovy, Zepbound, Mounjaro. FDA approval is indication-specific — confirm the right medication with your prescriber.
Is GLP-1 therapy FDA-approved for Prediabetes?
FDA approval is indication-specific. Some GLP-1 medications are FDA-approved for Prediabetes or a closely related indication, while others are prescribed off-label under clinical judgment. Always verify the approved indication for your specific medication.
Sources
- CDC Prediabetes Statistics
- Diabetes Prevention Program (DPP)
- NEJM — DPP results
- ADA Prediabetes Risk Test
Educational content; not a substitute for professional medical advice. Always consult a licensed clinician.
Diagnostic algorithm
How Prediabetes is diagnosed
Who diagnoses: Primary care provider. This is the standard clinical algorithm — not self-diagnosis guidance. Always work with your clinician for actual diagnosis.
- 1
Screen high-risk patients
Adults with BMI ≥25 + 1 risk factor (family history, hypertension, dyslipidemia, PCOS, sedentary)
Threshold: USPSTF: screen ages 35-70 with overweight/obesity
- 2
A1C blood test
Single sample sufficient for screening
Threshold: A1C 5.7-6.4% = prediabetes range
- 3
Alternative: fasting plasma glucose
After 8-hour fast
Threshold: FPG 100-125 mg/dL = impaired fasting glucose
- 4
Risk stratification
Calculate diabetes risk (CDC Prediabetes Risk Test) + comorbidity burden
Threshold: ~30% progress to T2D within 5 years untreated
- 5
Intervention recommendation
Diabetes Prevention Program (CDC-recognized lifestyle intervention) OR metformin for high-risk patients
Threshold: DPP achieves 58% T2D risk reduction
Source: ADA Standards of Care + USPSTF Recommendation Statement
Treatment decision criteria
When does a GLP-1 fit Prediabetes?
Criteria prescribers commonly weigh. Treatment decisions are your prescriber's — these are the factors that inform that decision.
Consider GLP-1 if…
- Concurrent obesity (BMI ≥30) — primary indication is obesity, prediabetes is comorbidity
- High progression risk + lifestyle intervention failure
- Patient also meets criteria for CVD-risk reduction (Wegovy)
Try alternatives first if…
- Prediabetes WITHOUT obesity — lifestyle intervention first
- Successful Diabetes Prevention Program completion (58% T2D risk reduction)
- Patient achieving glycemic improvement with diet + exercise alone
- Off-label cost-benefit unfavorable
First-line alternatives for Prediabetes
- Diabetes Prevention Program (DPP)
- CDC-recognized; 58% T2D risk reduction over 3 years; often insurance-covered
- Metformin
- Per ADA for high-risk prediabetes; reduces T2D progression ~31%
- Lifestyle intervention
- Foundation: 5-7% weight loss + 150 min/week activity